%0 Journal Article %T Which criteria should we use to evaluate the efficacy of immunecheckpoint inhibitors? %A Kataoka, Yuki %A Hirano, Katsuya %J Annals of Translational Medicine %D 2018 %B 2018 %9 %! Which criteria should we use to evaluate the efficacy of immunecheckpoint inhibitors? %K %X Immune-checkpoint inhibitors (ICI) have innovated the treatment of many different types of advanced cancer. Two important distinctions between ICI and other modalities are durable response (DR) and pseudoprogression (1,2). %U https://atm.amegroups.org/article/view/19463 %V 6 %N 11 %P 222 %@ 2305-5847